A unique drug is on the right pathway to success, as Oncolytics Biotechnology (ONCY) is pushing Reolysin through the pipeline. David Williamson from Motley Fool reported that this cancer medication is based off a common virus, incidentally referred to as the new “Cancer-Killing Virus.” This drug most recently passed its Phase II Metastatic Melanoma trial. The results have shown shrinkage in tumors; however, market skepticism still exists due to lack of data in overall survival rate. The continuation of these trials will be the key indication of whether this drug will indeed alter the course of cancer treatment, or remain science fiction.
View the full article here (http://www.fool.com/investing/general/2013/05/22/a-new-cancer-killing-virus.aspx).
Categories: cancer, COMPANIES, The Healthcare Investor
